Media

Bio-Path is a biotechnology company focused on the clinical development of life-saving therapeutics by utilizing DNAbilize™, the company’s novel patented method for producing antisense DNA therapeutics for a broad spectrum of indications, including cancer. Our lead product candidate, prexigebersen (Liposomal Grb2), formerly BP1001, is currently in Phase 2 studies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Our second drug candidate, a liposomal antisense drug called BP1002 (Liposomal Bcl2), is ready to enter the clinic, where it will be evaluated for treatment of lymphoma.

For media Inquiries
media@biopathholdings.com

Presentations & Publications

View Our Publications